# Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer

> **NCT00866905** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 168 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Ixabepilone
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT00866905
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2014-07
- **Final completion:** 2014-10
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2021-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00866905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00866905, "Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00866905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*